^
    Back
    Association details:
    Biomarker:PIK3CA H1047R + PIK3CA D959N + ER E380Q
    Cancer:HER2 Negative Breast Cancer
    Drug:Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Front Endocrinol (Lausanne)
    Title:

    Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature

    Published date:
    10/08/2021
    Excerpt:
    ...60-year-old female who presented with nausea and vomiting as the first manifestation after treated with abemaciclib (a CDK4/6 inhibitor) plus fulvestrant for 23 months due to bone metastasis of ILC…All three tumor samples carried PIK3CA p.H1047R, which is one of the most common mutation of PIK3CA in breast cancer. What’ more, the sample of metastatic lesion was found to have acquired PIK3CA p.D959N (Figure 4A) and ESR1 p.E380Q mutation...Our results suggest that ESR1 and PIK3CA mutations are acquired resistance mechanism of CDK4/6 inhibitor plus endocrine therapy...
    Secondary therapy:
    fulvestrant
    DOI:
    https://doi.org/10.3389/fendo.2021.659537